MP HC: Period Spent on Furlough Not to be Counted Towards Eligible Service for Calculating Pension || Orissa HC: Once a Citizen is Duly Employed, He Cannot be Whimsically Removed || Calcutta HC: Failure to Examine Weapon becomes Fatal in Cases of Circumstantial Evidence || Delhi HC: Prison Authorities Can Consider a Particular Case for Grant of Parole || Delhi HC: Can Arrest Accused after Curing Procedural Defects of Prior 'Illegal Arrest' || Del. HC: For Purpose of Maintenance, DV Act Doesn’t Distinguish between First or Subsequent Marriage || Delhi HC: Any Self-Declared Information on Matrimonial Portal is Not Reliable Proof of Income || P&H HC: Authority Must Not Dismiss Appeal Merely because Accused did Not Sign the Petition || SC: It is a Pleader’s Duty to Apprise the Court and Other Parties of his Client’s Death || SC: For Mandatory Injunction under SRA, Breach of Obligation Must be Specifically Established

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :